Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;31(6):2062-2068.
doi: 10.1038/s41591-025-03628-4. Epub 2025 Mar 30.

Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial

Affiliations
Free article
Randomized Controlled Trial

Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial

Job J Herrmann et al. Nat Med. 2025 Jun.
Free article

Abstract

Fluid restriction is frequently recommended to patients with chronic heart failure, but randomized clinical trials assessing the effects of fluid restriction remain scarce. In this multicenter open-label trial, outpatients with chronic heart failure were randomized to receiving advice for liberal fluid intake versus receiving advice for fluid restriction, up to 1,500 ml per day of fluid intake. The primary outcome of the trial was health status after 3 months, as assessed by the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS). Secondary outcomes included thirst distress and safety events. Among 504 randomized patients (67.3% male), the KCCQ-OSS after 3 months was 74.0 in the liberal fluid intake group versus 72.2 in the fluid restriction group, with a mean difference after adjustment for baseline scores of 2.17 (95% confidence interval -0.06 to 4.39; P = 0.06), indicating that the primary outcome was not met. Thirst distress was higher in the fluid restriction group and no differences were observed for safety events between the two groups. These findings question the benefit of fluid restriction in chronic heart failure. ClinicalTrials.gov registration: NCT04551729 .

PubMed Disclaimer

Conflict of interest statement

Competing interests: H.-P.B.-L.R. has received research grants from Innovative Health Initiative Joint Undertaking and Roche Diagnostics, received consulting fees from Astra Zeneca, Boehringer Ingelheim, Novartis, Roche Diagnostics and Vifor Pharma, received honoraria from Roche Diagnostics and participated on an Advisory Board of CeleCor Therapeutics. S.S.-v.W. has received research grants from Boehringer Ingelheim, CRL funds and ZonMW, received honoraria from Astra Zeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Roche Diagnostics and Pfizer, and is a member of the board of the Werkgroep Cardiologisch Centra Nederland and Stichting Perfusie. P.v.d.M. has received research grants from Astra Zeneca, Pfizer, Pharma Nord, Novo Nordisk, Ionis and Vifor Pharma, honoraria from Astra Zeneca, Boehringer Ingelheim, BridgeBio, Daiichi Sankyo, Ionis, Novartis, Novo Nordisk, Pfizer, Pharma Nord, Pharmacosmos and Vifor Pharma, and participated on an Advisory Board for CorHeart. J.L.J. has received research grants from Abbott, Applied Therapeutics, Astra Zeneca, HeartFlow and Novartis, received consulting fees from Abbott, Applied Therapeutics, Astra Zeneca, Beckman, Boehringer Ingelheim, Bristol Myers, Intellia, Jana Care, Novartis, Pfizer, Merck, Roche Diagnostics and Siemens, participated on an Advisory Board for Abbott, AbbVie, Bayer, CVRx, Roche Diagnostics and Takeda, is a member of the board of American College of Cardiology and Imbria Pharmaceuticals, and has stock (options) in Imbria Pharmaceuticals and Jana Care. A.B.-G. has lectured and/or participated in advisory boards for Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics and Vifor Pharma. D.H.F.G. received a speaker’s fee from Novartis and travel support from Astra Zeneca. R.R.J.v.K. received consulting fees from Novo Nordisk and Roche Diagnostics, honoraria from Hippocrates Academy and is a fiduciary member of the ESC working group on Peripheral Artery and Aortic Disease. The other authors declare no competing interests.

References

    1. Eng, S. H. et al. Thirst and factors associated with frequent thirst in patients with heart failure in Spain. Heart Lung 50, 86–91 (2021). - DOI - PubMed
    1. van der Wal, M. H. L., Waldreus, N., Jaarsma, T. & Kato, N. P. Thirst in patients with heart failure in Sweden, the Netherlands, and Japan. J. Cardiovasc. Nurs. 35, 19–25 (2020). - DOI - PubMed
    1. van der Wal, M. H. L., Jaarsma, T., Jenneboer, L. C. & Linssen, G. C. M. Thirst in stable heart failure patients; time to reconsider fluid restriction and prescribed diuretics. ESC Heart Fail. 9, 2181–2188 (2022). - DOI - PubMed - PMC
    1. Vazir, A. et al. Decongestion strategies in patients presenting with acutely decompensated heart failure: a worldwide survey among physicians. Eur. J. Heart Fail. 25, 1555–1570 (2023). - DOI - PubMed
    1. Hoog, L., Stromberg, A., Waldreus, N. & Nymark, C. A national survey of healthcare professional’s clinical practice on fluid intake in patients with heart failure. Abstract. Eur. J. Heart Fail. 26 (S2), 3–643 (2024).

Publication types

Associated data